Member Info for Adastra

As cable falls to 115 and a historic low, Smith and Nephew must be top of the list for transatlantic predators. That's a great position to be in as the company is emerging strongly from Covid. It needs the strengthening share price to maintain its UK independence and the underlying possibility of a bid increases as cable decreases. A really solid hold if stagflation materialises as 80% of financial analysts cutrently predict. Solid.

Too many reasons why reinvesting the divi and buying are the best value in the market.

Given the last positive trading update Smith and Nephew is now seriously vulnerable to an opportunistic bid at this level. Cable rate and prospects expose S&N at a level not seen since 2014. Critical time imo for the company. Defending against a fair price bid of around £17 would be difficult for BoD.......interesting for investors on all fronts.

If this weakness in the market holds its a great opportunity to reinvest tomorrow's divi....I certainly am!.Solid company with well above market prospects looking at any date horizon. Share price is totally out of sync with future here.

Did a good job as president of Siemens Healthineers and oversaw radical change in strategy that exploited and stimulated new market opportunities. Smith and Nephew is ripe and on-track, just needs a firm hand on the tiller hence his appointment. Solid.

He's picked up a wad of share options with an exercise price of £13.12 (well above the current level), in lieu of severance options from his previous post. That's a good incentive to stabilise and push the company forward quickly. It would also be a prudent time to make an initial purchase on the premise that any rapid progress or novel changes that he institutes will put S&N centre stage with analysts who are already cautiously bullish without conviction. The upward trend is firmly set after the previous bottoming. Given the current pullback commensurate with the wider market I would expect the company soon to start to disassociate the FTSE trend and cut it's own path as a dependable recession-proof health share in an ever expanding arena. I'm a long term player so happy to hold not fold. Solid.

Solid progress in a field with a huge backlog of elective surgery going into the horizon. Not many better shares to be holding at this level with a recession probable. Sound and trusted company with unequalled provenance and dividend record.
New CEO has all the street cred to make this motor in the coming months as upgrades to earnings kick in. Understate and over- deliver is the best way to quell any dissent.

But to re-iterate, if it can meet its growth and margin targets the company's multiple falls to 19 – a big discount to American rivals

Getting so close to a major reversal in the 'Covid Decline' here. Imminent - next fortnight should seal the upswing as investors spot the trend.

20ma up thro 50ma and set to attack 200day ma with 50ma moving north.......get ready for the 200ma breakout then boom....

Nice to see that Deepak's initially holding is locked in at £13.12. These are effectively the carry-over incentives from previous employment translated into S&N but the strike price is very encouraging. Good news and hopefully followed by his own purchases. Onward and upward.

Telegraph financial analyst/tipster gives good analysis of S&N in this weekend's paper.
https://www.telegraph.co.uk/business/questor/

Nice to see last year's doom mongers abandoning ship and realising the price is only going up from here....

Having done your research youve realised the huge respect and provenance that Smith and Nephew has in the global surgical and medical community. Ongoing education for practitioners and newcomers is unequalled and regional centres of excellence ensure global consistency.
Barriers to entry are huge and the forecast for the sector is secure and pretty recession-proof. In light of that, the shares trade at a small but well justified premium. The 100yr plus divi record speaks volumes. Potential bidders are a constant presence due to the earnings horizon in all political and economic landscapes. The growth in ACS units and proliferation of sports related injuries and joint replacements gives huge scope for upgrades as will the brand new huge Malaysian logistics facility in H2. Any bid would have to reflect the outlook as it would appear that S&N is leading others post Covid. I realistically, along with several analysts, value the shares around £18, before recent figures. Any bid would certainly not succeed imo below that. J&J however has the underlying split issue which may complicate their potential moves.

As you say, with cable below 125 Johnson and Johnson must be in a real quandary. It's all geared to split into Mediacal/pharma and Healthcare within the next 18 months and S&N is a screaming buy for the former post-split. S&N traction in medical devices is leading the pack out of Covid and is a jigsaw fit for J&J. Plus it would give J&J significant US tax benefits......must be wringing it's hands at present. I'm happy whatever as this is still massively undervalued in the coming commercial landscape. Solid recession beater with a fair progressive unbroken divi for over 100yrs.

Fully loaded

Read all my posts - think you'll get the idea. Long term investor and holder. Just stating the obvious.

Magic! What a superb and solid platform for 2022 and Deepak to make his mark....£18 firmly in the crosshairs now. Waiting the analyst comments and upgrades with delight. Spot on.

Cosh....

Agreed....Lots riding on the t/u and Deepak's feedback. If it even smells of accelerating post Covid and/or Deepak buys into the lows then it could really sparkle. Otherwise, as you point out, with Sterling under the cosy S&N looks a very tasty recession-proof morsel to a Yankee predator.